&nbsp;

Aug 2023

Drug

venetoclax

Other Name(s): Venclexta®

Quick Link(s):

May 2024

Drug

midostaurin

Other Name(s): Rydapt®

Quick Link(s):

Jun 2022

Drug

pegaspargase

Other Name(s): Oncaspar®

Quick Link(s):

Dec 2022

Drug

inotuzumab ozogamicin

Other Name(s): Besponsa®

Quick Link(s):

Jul 2023

Drug

dinutuximab

Other Name(s): Unituxin®

Quick Link(s):

Drug Monograph

Jun 2023

Drug

gemtuzumab ozogamicin

Other Name(s): Mylotarg®

Quick Link(s):

Jun 2022

Drug

gilteritinib

Other Name(s): Xospata®

Quick Link(s):

Jul 2023

Drug

liposomal DAUNOrubicin / liposomal cytarabine

Other Name(s): Vyxeos®

Quick Link(s):

Dec 2023

Drug

thiotepa

Other Name(s): Tepadina®

Quick Link(s):

Drug Monograph

Jan 2023

Regimen

EPCO; EPCO(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

High Cost Therapy Funding Program

Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

, Collapse Show fewer tags

Drugs Used:

epcoritamab

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

GLOF; GLOF(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

High Cost Therapy Funding Program

Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma